Quadruple negative breast cancer

Receptor-negative breast cancer: The quadruple threat

Cancers, Free Full-Text

CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression

Merck's Keytruda gets a foothold in breast cancer market long held by Roche

EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple

Quadruple-Negative Breast Cancer: An Uneven Playing Field

ACSL4: Biomarker, Mediator and Target in Quadruple Negative Breast

Receptor-negative breast cancer: The quadruple threat - Faculty of Health Sciences

Enzalutamide Overcomes Dihydrotestosterone-Induced Chemoresistance in Triple- Negative Breast Cancer Cells via Apoptosis

BRE1121 Triple negative breast cancer with normal tissue array (most of triple negative TNBC), including pathology grade, TNM, clinical stage and IHC markers (ER, PR, Her-2), 112 cases/112 cores -

ACSL4: Biomarker, Mediator and Target in Quadruple Negative Breast Cancer

5 Treatments for Triple-Negative Breast Cancer and Common Side Effects

Triple-negative breast cancer: treatment challenges and solutions. - Document - Gale Academic OneFile

PDF) Integrated copy number and miRNA expression analysis in triple negative breast cancer of Latin American patients